drugset / Trial / NCT01908140

Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01908140

Phase 3 Completed 933 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of the study is to compare the efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate and salmeterol/fluticasone propionate in patients with chronic obstructive pulmonary disease (COPD)

Timeline

Start
2013-09
Primary completion
2014-08
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Aclidinium Small molecule 400 ug
Comparator Fluticasone propionate Other / unclassified 500 ug
Subject Formoterol Other / unclassified 12 ug
Comparator Salmeterol Other / unclassified 50 ug